RxDoctor Payments Data

William Woolery, MD

Pulmonary Disease · Sedalia, MONPI 1760477475

Payments from drug & device makers

$1,746in general payments, 2019–2025

Across 92 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$578
  • Boehringer Ingelheim$474
  • Sanofi$220
  • GSK$113
  • Mylan Specialty L.p.$81
  • Sanofi-aventis U.S. LLC$57
  • plus $222 from 9 others

What the payments were for

  • Food & beverage$1,67396%
  • Education$734%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,746 in reported general payments places this provider in the 45th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$173,045
Medicare patients
938
Services billed
3,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate19$277,450
EliquisApixaban115$98,026
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$48,861
Breo ElliptaFluticasone/Vilanterol77$46,235
XareltoRivaroxaban31$36,642
OzempicSemaglutide37$36,222
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$20,310
Combivent RespimatIpratropium/Albuterol Sulfate19$19,654
RexultiBrexpiprazole37$19,273
JardianceEmpagliflozin12$17,394
SymbicortBudesonide/Formoterol Fumarate47$15,332
Fluticasone-SalmeterolFluticasone Propion/Salmeterol73$14,468
Spiriva RespimatTiotropium Bromide14$13,167
Albuterol Sulfate HfaAlbuterol Sulfate226$8,810
Incruse ElliptaUmeclidinium Bromide19$6,615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Combivent Respimat, Jardiance, Spiriva Respimat$474$327,66464 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arexvy$113$105,333166 claims
PfizerEliquis, Abrysvo$43$101,429126 claims
Johnson & JohnsonXarelto$15$36,64231 claims
Novo NordiskOzempic$19$36,22237 claims
AstraZenecaBreztri Aerosphere, Symbicort$578$35,64273 claims
Otsuka America Pharmaceutical, Inc.Rexulti$17$19,27337 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Sedalia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →